Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.885
-0.055 (-2.84%)
Oct 8, 2026, 12:18 PM EDT - Market open
Inhibikase Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $6.00. The average 1-year stock price forecast is 218.30% higher than the current stock price, while the lowest is $3.00 (+59.15%) and the highest is $8.00 (+324.40%).
Price Target: $6.00 (+218.30%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +165.25% | Sep 15, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +324.40% | Aug 14, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $5 | Buy | Maintains | $5 | +165.25% | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +324.40% | Jul 31, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $6 | Buy | Maintains | $6 | +218.30% | Jul 28, 2026 |
Financial Forecast
Revenue This Year
250.00K
Revenue Next Year
333.33K
from 250.00K
Increased by 33.33%
EPS This Year
-0.45
EPS Next Year
-0.43
from -0.45
EPS and Forward PE are based on non-GAAP adjusted numbers.